Stockscreener 앱 받기
65.27
3.38%
-2.28
시간 외 거래:
65.27
Vaxcyte Inc 주식(PCVX)의 최신 뉴스
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet - Zacks Investment Research
Vaxcyte EVP, COO Jim Wassil sells $1.56m in shares By Investing.com - Investing.com South Africa
Vaxcyte EVP, COO Jim Wassil sells $1.56m in shares - Investing.com
Vaxcyte Finalizes $575M Convertible Senior Notes and Equity Offering in October 2026 - Kalkine Media
Vaxcyte Closes Offerings of Common Stock, Warrants, and Senior Notes - marketscreener.com
Vaxcyte Announces Closing of $1.15 Billion Public Offerings - GlobeNewswire
Vaxcyte Inc Stock (PCVX) Moved Up by 9.47% on Oct 9: What Signal Does It Send? - TradingKey
Latham Advises on Vaxcyte Concurrent Public Offerings of Common Stock Pre Funded Warrants - Latham & Watkins LLP
Vaxcyte Announces Pricing for $500M Convertible Notes and 7.4M Share Offering - Kalkine Media
About $500 million is expected from stock and $500 million from bonds. Vaxcyte plans to fund vaccine work. - Stock Titan
Vaxcyte prices US$1B in stock, warrants and convertible notes - Mugglehead Investment Magazine
Vaxcyte stock reports OPUS-1 success after a 9.65 percent drop - AD HOC NEWS
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes - GlobeNewswire Inc.
Vaxcyte Announces Pricing of Concurrent Public Offerings of - GlobeNewswire
Biotech Stocks At 52-Week HighsPCVX +31% On Phase 3 Results, INFU, ILMN +7%, CRL+7%, HTFL +5% - RTTNews
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? - Zacks Investment Research
Two proposed $500 million offerings could fund Vaxcyte vaccine trials and U.S. launch preparations. - stocktitan.net
Vaxcyte stock falls on $1B dual offering launch - Yahoo Finance
Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge - The Motley Fool
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes - marketscreener.com
Vaxcyte, Inc.Common Stock (Nasdaq:PCVX) Stock Quote - FinancialContent
An officer proposes to sell $1.65M in Vaxcyte (PCVX) shares acquired by exercising stock options. - Stock Titan
An officer proposes selling Vaxcyte (PCVX) shares acquired by exercising stock options for cash. - stocktitan.net
Vaxcyte, Inc. (PCVX) Stock Price, News, Quote & History - ca.finance.yahoo.com
Vaxcyte EVP Jim Wassil Executes Stock Option and Sells Shares via Rule 10b5-1 Plan - Kalkine Media
A 2,250-share sale is proposed by Vaxcyte (PCVX) officer James Wassil. - Stock Titan
Total common shares outstanding of Vaxcyte, Inc. – HAN:5VA - TradingView
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research
Trading the Move, Not the Narrative: (PCVX) Edition - Stock Traders Daily
Vaxcyte EVP Jim Wassil sells $163,862 in company stock By Investing.com - Investing.com South Africa
Vaxcyte CFO Andrew Guggenhime Forfeits 7,155 Shares, 7% of Holdings at $60.36 Each - Kalkine Media
Vaxcyte EVP Jim Wassil sells $163,862 in company stock By Investing.com - Investing.com Nigeria
Vaxcyte EVP Jim Wassil sells $163,862 in company stock By Investing.com - Investing.com Canada
Vaxcyte EVP Jim Wassil sells $163,862 in company stock - Investing.com
Vaxcyte (PCVX) officer plans stock sale after RSU vest - Stock Titan
Vaxcyte at Cantor conference: broad vaccine bet nears key test By Investing.com - Investing.com Canada
PCVX: VAX-31 phase III data expected by end of October, targeting broader pneumococcal protection - TradingView
Vaxcyte EVP Jim Wassil sells $163,862 in company stock - Investing.com
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes By Investing.com - Investing.com Nigeria
Why Are Vaxcyte (NASDAQ:PCVX) Shares Under Pressure After A Timeline Update? - Kalkine Media
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes By Investing.com - Investing.com Canada
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes By Investing.com - Investing.com UK
Vaxcyte Executive Sells Shares for Tax Obligations - Intellectia AI
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - The Globe and Mail
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know - The Globe and Mail
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - The Globe and Mail
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - The Motley Fool
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm - The Motley Fool
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - Yahoo Finance
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know - The Globe and Mail
0.91%
0.04%
자본화:
|
볼륨(24시간):